Axent Biosciences is a therapeutics company pioneering next-generation stem cell therapies to address unmet medical needs in human health. Spun out of Professor David Schaffer’s Lab at UC Berkeley, Axent leverages over 20 years of stem cell expertise and more than a decade of biomaterials engineering to overcome key bottlenecks in the clinical development pipeline. Our proprietary AXgel cell cultivation platform enables scalable, high-quality, and cost-effective manufacturing of stem cell therapeutics, unlocking the potential for broad accessibility. With a lead indication in Parkinson’s Disease, Axent is focused on transforming the cell therapy treatment landscape, driven by a mission to make stem cell therapies accessible and affordable for all.
